• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Acta Radiologica >Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy.
【24h】

Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy.

机译：射频消融化疗后结直肠肝转移。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Radiofrequency ablation (RFA) continues to evolve, improving the potentials of this technique. It is now a widely used procedure in the treatment of patients with unresectable colorectal liver metastases, increasing the number of potentially curable patients. PURPOSE: To evaluate the long-term survival of patients treated by RFA for colorectal liver metastases after downstaging by systemic chemotherapy. MATERIAL AND METHODS: In a retrospective review of our prospective colorectal liver metastasis RFA database, 36 patients (20 males, 16 females; median age 67 years) were identified during an 8-year period (1999-2007). All patients were initially unsuitable for local treatment, and referred to systemic chemotherapy by our multidisciplinary team. Multinodularity and/or location of tumor was the main cause of patients being unsuitable for local treatment. Chemotherapy mainly consisted of 5-fluorouracil and leucovorin combined with oxaliplatin or irinotecan. After downstaging with chemotherapy, patients were treated by RFA. Patients with extrahepatic disease were excluded from RFA treatment. Pre- and posttreatment evaluation was performed with multidetector computed tomography (MDCT) scans. RESULTS: The median time from diagnosis of hepatic metastases to first RFA was 10 months. A total of 158 tumors were treated with RFA during the study period. Median follow-up period was 27 months. The estimated median survival time after diagnosis of hepatic metastasis was 39 months, with a 5-year survival rate of 34%. CONCLUSION: In selected patients with colorectal liver metastases downstaged by chemotherapy, RFA is an important modality that may contribute to improved survival. Furthermore, all patients responding to systemic chemotherapy should be re-evaluated by a multidisciplinary team.
机译：背景：射频消融（RFA）不断发展，提高了这项技术的潜力。现在，它已广泛用于治疗无法切除的结直肠肝转移患者，从而增加了可能治愈的患者数量。目的：评估经全身化疗降低分期后接受RFA治疗的结直肠肝转移患者的长期生存率。材料与方法：在回顾性前瞻性结直肠肝转移RFA数据库中，在8年期间（​​1999-2007年）确定了36例患者（男20例，女16例;中位年龄67岁）。最初所有患者均不适合局部治疗，并由我们的多学科团队转介全身化疗。多结节和/或肿瘤的位置是患者不适合局部治疗的主要原因。化学疗法主要由5-氟尿嘧啶和亚叶酸钙联合奥沙利铂或伊立替康组成。降低化疗分期后，患者接受RFA治疗。肝外疾病患者不接受RFA治疗。治疗前和治疗后的评估是使用多探测器计算机断层扫描（MDCT）扫描进行的。结果：从诊断出肝转移到首次RFA的中位时间为10个月。在研究期间，共用RFA治疗了158个肿瘤。中位随访期为27个月。诊断为肝转移后的估计中位生存时间为39个月，5年生存率为34％。结论：在某些化疗后结直肠肝转移患者中，RFA是一种重要的治疗手段，可能有助于提高生存率。此外，应由多学科团队对所有对全身化疗有反应的患者进行重新评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号